[ Pharmaceutical Sciences Asia - ONLINE ]
Print ISSN 2586-8195 E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: 10.29090/psa.2019.03.018.0006Pharm Sci Asia 2019; 46(3), 175-183
 

Treatment of COPD in one university hospital setting in Thailand:the real-life prescribing patterns and treatment expenditures

Thidarat Samarnkongsak1,2, Montarat Thavorncharoensap1, Theerasuk Kawamatawong3* , Oraluck Pattanaprateep4, Farsai Chanjaruporn1, Montaya Sunantiwat1

1 Division of Social and Administrative Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University,Bangkok 10400, Thailand
2 Department of Pharmacy, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
3 Division of Pulmonary and Critical Care Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
4 Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand


This study aims to examine prescribing patterns of COPD medications, adherence to The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 guideline, and impact of the adherence on clinical and economic outcomes. A retrospective study was conducted at Ramathibodi hospital. All COPD patients receiving treatment during July 1- December 31, 2012 were identified from electronic database. Index date was determined as the first date with FEV1 during the recruitment period. Data on treatment, cost, and clinical outcomes were reviewed for 1 year after index date. The results were included 109 patients. 84 patients (77.06%) and 25 patients (22.94%) were classified into group 1 (FEV1 ≥ 50%) and group 2 (FEV1 < 50%), respectively. It was found that group 1 reported significantly lower exacerbation rate (26.19% vs 80.00%) than group 2. SABA/SAMA was the most prescribed drugs (97.61% in group 1 and 100% in group 2). Overtreated with ICS was common (63.09%) with FEV1 ≥ 50%. Average annual treatment expenditure per capita was US$ 411 for group 1 and US$ 703 for group 2. No association between adherence to GOLD 2013 guidelines and clinical or economic outcomes was identified, possibly due to short duration of study. Adherence to GOLD 2013 guideline was sub-optimal. To promote the adherence to GOLD 2013 guideline, further long-term and well developed studies are clearly needed.


Keyword:

COPD; Adherence; Guideline; Prescribing patterns; Thailand




Download full paper (PDF File size: 1,134.50 KB.)





Vol.46
No.4
October - December 2019

See other volume

 


Vol.46
No.3
July - September 2019

See other volume

 


Vol.46
No.2
April - June 2019

See other volume

 


Vol.46
No.1
January - March 2019

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register



    Copyright © 2017
    Faculty of Pharmacy, Mahidol University, THAILAND